Loading
A phase 3 trial of Acalabrutinib, Rituximab and Chlorambucil in chronic lymphocytic leukaemia, run by AstraZeneca, active and no longer recruiting.
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia is a phase 3 interventional study registered as NCT04075292 by AstraZeneca, with 155 participants enrolled, started 2020-01-20 and due to reach its primary completion in 2024-01-03. Interventions recorded: Acalabrutinib, Rituximab and Chlorambucil. Results have been posted on the registry.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
155 enrolled.
NA indicated that the median, lower and upper limit of 95% CI were not estimable due to insufficient number of participants with events.; Figures from the ClinicalTrials.gov results section (first posted 2025-01-30), not from a publication · 95% CI 11.53 to 17.54
Source| Endpoint | Arm | n | Value | HR (95% CI) | p | Source |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) Assessed by BICRprimary | Acalabrutinib | 77 | NA indicated that the median, lower and upper limit of 95% CI were not estimable due to insufficient number of participants with events.; Figures from the ClinicalTrials.gov results section (first posted 2025-01-30), not from a publication | 0.08 (0.03 to 0.18) | <0.0001 | link |
| Chlorambucil Plus Rituximab | 78 | 15.54 months |
Shares Acalabrutinib, Rituximab, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, AstraZeneca and the tag pipeline.
Shares Chronic lymphocytic leukaemia, first treatment, Rituximab, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, first treatment, Chronic lymphocytic leukaemia, Monoclonal antibodies and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acalabrutinib, Chronic lymphocytic leukaemia, AstraZeneca, Small-molecule kinase inhibitors and the tag pipeline.